Brand-New bioLIVE China in 2019
LEADING THE BIOPHARMACEUTICAL TRENDS IN AISA
In recent years, with the rapid development of cutting edge bio technologies and the mass emerge of new target drugs and cytotherapies, the biopharmaceutical industry is entering a blooming new age. In view of the global marketing size, the sales of biopharmaceutical drugs are expected to exceed 1/3 of the overall drug sales income. As per the statistics by InSight, the registrations of domestic bio drugs counted for 616 in year 2017, which exceeded the highest in the recent 5 years. As is predicted by Frost & Sullivan, the market size of China’s bio drugs will reach 326.9 billion RMB, with its increase rate ranking among the highest countries in the world.
In 2019, the brand new bioLIVE China will be launched, as an upgrade from the seven-year-old biopharmaceutical platform BioPh China. bioLIVE China 2019 will focus on life science & technology and innovative drugs, aiming to lead industrial trends and booster development in the biopharmaceutical area.